SG11202103031SA - Immunoablative therapies - Google Patents
Immunoablative therapiesInfo
- Publication number
- SG11202103031SA SG11202103031SA SG11202103031SA SG11202103031SA SG11202103031SA SG 11202103031S A SG11202103031S A SG 11202103031SA SG 11202103031S A SG11202103031S A SG 11202103031SA SG 11202103031S A SG11202103031S A SG 11202103031SA SG 11202103031S A SG11202103031S A SG 11202103031SA
- Authority
- SG
- Singapore
- Prior art keywords
- immunoablative
- therapies
- immunoablative therapies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Psychology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18198491.5A EP3488851A1 (en) | 2018-10-03 | 2018-10-03 | Immunoablative therapies |
PCT/US2019/054395 WO2020072713A1 (en) | 2018-10-03 | 2019-10-03 | Immunoablative therapies |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202103031SA true SG11202103031SA (en) | 2021-04-29 |
Family
ID=63762311
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202103031SA SG11202103031SA (en) | 2018-10-03 | 2019-10-03 | Immunoablative therapies |
Country Status (14)
Country | Link |
---|---|
US (2) | US11446314B2 (en) |
EP (2) | EP3488851A1 (en) |
JP (1) | JP2020059703A (en) |
KR (1) | KR20210072039A (en) |
CN (1) | CN113164497A (en) |
AU (1) | AU2019355004A1 (en) |
BR (1) | BR112021006280A2 (en) |
CA (1) | CA3113969A1 (en) |
EA (1) | EA202190927A1 (en) |
ES (1) | ES2863369T3 (en) |
MX (1) | MX2021003797A (en) |
SG (1) | SG11202103031SA (en) |
WO (1) | WO2020072713A1 (en) |
ZA (1) | ZA202102727B (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220130253A (en) * | 2018-11-14 | 2022-09-26 | 에이브이엠 바이오테크놀로지, 엘엘씨 | Stable Glucocorticoid Formulation |
CA3168378A1 (en) * | 2020-02-28 | 2021-09-02 | Avm Biotechnology, Llc | Lypmphocyte population and methods for producing same |
CN115666583A (en) | 2020-04-29 | 2023-01-31 | Avm生物技术有限责任公司 | Glucocorticoid Receptor (GR) modulators for the treatment of SARS-COV-2 virus |
WO2021247000A1 (en) * | 2020-06-01 | 2021-12-09 | Avm Biotechnology, Llc | Methods of treatment using icam-modulating agents |
KR20220163638A (en) | 2021-06-03 | 2022-12-12 | 현대모비스 주식회사 | Brake Apparatus for Vehicle and Control Method Therefor |
WO2023034377A1 (en) | 2021-09-01 | 2023-03-09 | Avm Biotechnology, Llc | Lymphocyte population and methods for producing same |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3368937A (en) * | 1965-01-26 | 1968-02-13 | Merck & Co Inc | Injectable solid steroid-anesthetic |
US5728388A (en) | 1989-10-03 | 1998-03-17 | Terman; David S. | Method of cancer treatment |
GB9323199D0 (en) | 1993-11-10 | 1994-01-05 | Falkenberg J H F | Leukaemia treatment |
US6406699B1 (en) | 1999-10-05 | 2002-06-18 | Gary W. Wood | Composition and method of cancer antigen immunotherapy |
IL146970A0 (en) | 2001-12-06 | 2002-08-14 | Yeda Res & Dev | Migration of haematopoietic stem cells and progenitor cells to the liver |
WO2003077864A2 (en) | 2002-03-15 | 2003-09-25 | Department Of Veterans Affairs, Rehabilitation R & D Service | Methods and compositions for directing cells to target organs |
MXPA04010927A (en) * | 2002-05-02 | 2006-01-30 | Univ Washington | Methods and compositions for treating t cell mediated inflammatory/autoimmune diseases and disorders in subjects having a glucocorticoid regulation deficiency. |
CN100436763C (en) * | 2002-05-08 | 2008-11-26 | Btu国际公司 | Plasma-assisted engine exhausting process |
EP2105136A3 (en) | 2002-05-17 | 2010-01-27 | Celgene Corporation | Pharmaceutical compositions for treating cancer |
JP3968334B2 (en) | 2002-09-11 | 2007-08-29 | 株式会社日立ハイテクノロジーズ | Charged particle beam apparatus and charged particle beam irradiation method |
GB0310593D0 (en) | 2003-05-08 | 2003-06-11 | Leuven K U Res & Dev | Peptidic prodrugs |
US20040247574A1 (en) | 2003-05-27 | 2004-12-09 | Christopherson Kent W. | Methods for enhancing stem cell engraftment during transplantation |
CA2592435C (en) | 2004-12-23 | 2017-03-28 | Ethicon, Incorporated | Treatment of stroke and other acute neural degenerative disorders using postpartum derived cells |
RU2468797C2 (en) * | 2005-06-09 | 2012-12-10 | Биолипокс Аб | Method and composition for treatment of inflammatory disorders |
BRPI0613770A2 (en) | 2005-07-22 | 2009-05-19 | Y S Therapeutics Co Ltd | anti-cd26 antibodies and methods of use of these |
US8278104B2 (en) | 2005-12-13 | 2012-10-02 | Kyoto University | Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2 |
GB0700058D0 (en) | 2007-01-03 | 2007-02-07 | Scancell Aps | Anti-tumor vaccine based on normal cells |
US20100247491A1 (en) | 2007-02-01 | 2010-09-30 | Christof Westenfelder | Potentiation of Stem Cell Homing and Treatment of Organ Dysfunction or Organ Failure |
US20090299269A1 (en) | 2008-05-29 | 2009-12-03 | John Foley | Vascular stimulation to aid intravascular cell replacement therapy |
ES2627043T3 (en) | 2008-06-09 | 2017-07-26 | Targazyme, Inc. | Increased effectiveness of cell therapy including treatment with alpha 1-3 fucoslitransferase |
WO2009152186A1 (en) | 2008-06-09 | 2009-12-17 | American Stem Cell, Inc. | Methods for enhancing cell therapy efficacy including treatment with cd26 peptidase inhibitors |
RU2645069C2 (en) | 2010-08-18 | 2018-02-15 | Авм Байотекнолоджи, Ллс | Compositions and methods for inhibition of stem cells and precursor cells binding with lymphoid tissue and for regeneration of germinal centers in lymph tissues |
US10426740B1 (en) | 2010-08-18 | 2019-10-01 | Avm Biotechnology, Llc | Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues |
PL3214091T3 (en) | 2010-12-09 | 2019-03-29 | The Trustees Of The University Of Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
EA201391059A1 (en) | 2011-01-18 | 2014-05-30 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | COMPOSITIONS FOR CANCER TREATMENT AND METHODS OF THEIR APPLICATION |
EP2532740A1 (en) | 2011-06-11 | 2012-12-12 | Michael Schmück | Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy |
EP2756521A4 (en) | 2011-09-16 | 2015-04-22 | Univ Pennsylvania | Rna engineered t cells for the treatment of cancer |
US20130287747A1 (en) | 2012-04-30 | 2013-10-31 | Allocure, Inc. | Methods of Treating Acute Kidney Injury Using Mesenchymal Stem Cells |
US10117896B2 (en) | 2012-10-05 | 2018-11-06 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
US11091543B2 (en) * | 2015-05-07 | 2021-08-17 | Swedish Orphan Biovitrum Ag | Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications |
KR20230147769A (en) | 2015-05-28 | 2023-10-23 | 카이트 파마 인코포레이티드 | Methods of conditioning patients for t cell therapy |
WO2018153984A1 (en) * | 2017-02-23 | 2018-08-30 | Universität Bern | Mtor inhibitor-corticoid combination therapy for multiple sclerosis |
SG11201907744QA (en) | 2017-04-01 | 2019-09-27 | Avm Biotechnology Llc | Replacement of cytotoxic preconditioning before cellular immunotherapy |
-
2018
- 2018-10-03 EP EP18198491.5A patent/EP3488851A1/en not_active Withdrawn
- 2018-12-20 US US16/227,068 patent/US11446314B2/en active Active
-
2019
- 2019-10-03 CN CN201980076619.1A patent/CN113164497A/en active Pending
- 2019-10-03 KR KR1020217013417A patent/KR20210072039A/en unknown
- 2019-10-03 CA CA3113969A patent/CA3113969A1/en active Pending
- 2019-10-03 JP JP2019182659A patent/JP2020059703A/en active Pending
- 2019-10-03 SG SG11202103031SA patent/SG11202103031SA/en unknown
- 2019-10-03 EA EA202190927A patent/EA202190927A1/en unknown
- 2019-10-03 EP EP19786713.8A patent/EP3860612A1/en active Pending
- 2019-10-03 US US17/281,016 patent/US20210338689A1/en active Pending
- 2019-10-03 WO PCT/US2019/054395 patent/WO2020072713A1/en unknown
- 2019-10-03 BR BR112021006280A patent/BR112021006280A2/en unknown
- 2019-10-03 ES ES19201254T patent/ES2863369T3/en active Active
- 2019-10-03 AU AU2019355004A patent/AU2019355004A1/en active Pending
- 2019-10-03 MX MX2021003797A patent/MX2021003797A/en unknown
-
2021
- 2021-04-23 ZA ZA2021/02727A patent/ZA202102727B/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2020059703A (en) | 2020-04-16 |
US20210338689A1 (en) | 2021-11-04 |
EP3488851A1 (en) | 2019-05-29 |
ZA202102727B (en) | 2022-05-25 |
WO2020072713A1 (en) | 2020-04-09 |
US20200108078A1 (en) | 2020-04-09 |
KR20210072039A (en) | 2021-06-16 |
BR112021006280A2 (en) | 2021-07-06 |
US11446314B2 (en) | 2022-09-20 |
EP3860612A1 (en) | 2021-08-11 |
MX2021003797A (en) | 2021-08-11 |
CN113164497A (en) | 2021-07-23 |
CA3113969A1 (en) | 2020-04-09 |
AU2019355004A1 (en) | 2021-05-06 |
ES2863369T3 (en) | 2021-10-11 |
EA202190927A1 (en) | 2021-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202102016B (en) | Combination therapies | |
IL274407A (en) | Combination therapies | |
IL271011A (en) | Triple combination antibody therapies | |
IL263680A (en) | Combination therapies | |
PT3810587T (en) | Substituted alkoxypyridinyl indolsulfonamides | |
ZA202102727B (en) | Immunoablative therapies | |
GB201800761D0 (en) | Interaction between blockchains | |
EP3423094A4 (en) | Gfral receptor therapies | |
ZA202102015B (en) | Combination therapies | |
IL291659A (en) | Combination therapies | |
HK1243598A1 (en) | Combination therapies | |
IL281526A (en) | Rail-switching unit | |
GB201901651D0 (en) | The geness project | |
GB201901639D0 (en) | The blockworld project | |
IL276999A (en) | Breastshield unit | |
GB201703907D0 (en) | Novel therapies for cancer | |
GB201916906D0 (en) | Combination therapies | |
GB2612702B (en) | Host-biome interactions | |
GB201902311D0 (en) | The nautica project | |
GB201807046D0 (en) | Combination | |
IL287667A (en) | Combination therapies | |
GB201908621D0 (en) | Construction set | |
GB201902722D0 (en) | The Krishi project | |
GB201819369D0 (en) | Maglee plane | |
GB201807559D0 (en) | Saddle |